MRX DEADLINE: Faruqi & Faruqi Reminds Marex Investors of Class‑Action Lead Plaintiff Deadline — December 8, 2025

Faruqi & Faruqi, LLP — a securities‑litigation law firm — announced on November 30, 2025 that investors in Marex Group plc (ticker: MRX) have until December 8, 2025 to file a motion to serve as lead plaintiff in a pending class‑action lawsuit. The suit claims that Marex and certain executives misled investors and failed to properly disclose significant financial irregularities. Allegations include that Marex sold over-the-counter financial instruments to itself; that there were inconsistencies between its subsidiaries and related parties (notably in intercompany receivables and loans); and that — because of these practices — the company’s public financial statements could not be relied upon. As a result, prior positive statements about Marex’s business, operations, and prospects are said to be materially misleading or without reasonable basis. The impetus for the lawsuit traces back to a report from NINGI Research, released August 5, 2025, which accused Marex of running a multi‑year accounting scheme involving off‑balance-sheet entities, fictitious transactions, and misleading disclosures to conceal losses and inflate profits. Examples cited include a $17 million fabricated receivable, inflated subsidiary profits, undervalued asset sales, and nearly $1 billion in concealed derivatives exposure via a Luxembourg fund—allegations that, if proven, could have substantially overstated Marex’s financial health. Faruqi & Faruqi encourages anyone who bought or acquired Marex securities between May 16, 2024 and August 5, 2025 — and believes they suffered losses — to contact partner James (Josh) Wilson directly at 877‑247‑4292 or 212‑983‑9330 ext. 1310 for more information. The firm also invites whistleblowers, former employees, shareholders, or others with relevant information about Marex’s conduct to reach out. #Marex #ClassAction #InvestorAlert #AccountingFraud #SlimScan #GrowthStocks #CANSLIM